Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Plank, J; Bodenlenz, M; Sinner, F; Magnes, C; Görzer, E; Regittnig, W; Endahl, LA; Draeger, E; Zdravkovic, M; Pieber, TR.
A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.
Diabetes Care. 2005; 28(5):1107-1112
Doi: 10.2337/diacare.28.5.1107
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Leading authors Med Uni Graz
- Pieber Thomas
- Co-authors Med Uni Graz
- Fließer-Görzer Evelyn
- Regittnig Werner
- Sinner Frank Michael
- Weiss Manfred
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- To investigate the pharmacodynamic profile and duration of action for five subcutaneous doses of insulin detemir (0.1, 0.2, 0.4, 0.8, and 1.6 units/kg; 1 unit = 24 nmol) and one subcutaneous dose of NPH insulin (0.3 IU/kg; 1 IU = 6 nmol). This single-center, randomized, double-blind, six-period, crossover study was carried out as a 24-h isoglycemic clamp (7.2 mmol/l) in 12 type 1 diabetic patients. Duration of action for insulin detemir was dose dependent and varied from 5.7, to 12.1, to 19.9, to 22.7, to 23.2 h for 0.1, 0.2, 0.4, 0.8, and 1.6 units/kg, respectively. Interpolation of the dose-response relationships for AUC(GIR) (area under the glucose infusion rate curve) revealed that a detemir dose of 0.29 units/kg would provide the same effect as 0.3 IU/kg NPH but has a longer duration of action (16.9 vs. 12.7 h, respectively). Lower between-subject variability was observed for insulin detemir on duration of action (0.4 units/kg insulin detemir vs. 0.3 IU/kg NPH, P < 0.05) and GIR(max) (maximal glucose infusion rate) (0.2 and 0.4 units/kg insulin detemir vs. 0.3 IU/kg NPH, both P < 0.05). Assessment of endogenous glucose production (EGP) and peripheral glucose uptake (PGU) resulted in an AOC(EGP) (area over the EGP curve) of 636 mg/kg (95% CI 279-879) vs. 584 (323-846) and an AUC(PGU) (area under the PGU curve) of 173 (47-316) vs. 328 (39-617) for 0.29 units/kg detemir vs. 0.3 IU/kg NPH, respectively. This study shows that insulin detemir provides a flat and protracted pharmacodynamic profile.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Blood Glucose - drug effects
- Blood Glucose - metabolism
- Cross-Over Studies -
- Diabetes Mellitus, Type 1 - drug therapy
- Double-Blind Method -
- Fatty Acids, Nonesterified - blood
- Female -
- Glucose - pharmacokinetics
- Glucose Clamp Technique -
- Humans -
- Hypoglycemic Agents - administration & dosage
- Hypoglycemic Agents - pharmacokinetics
- Injections, Subcutaneous -
- Insulin - administration & dosage
- Insulin - analogs & derivatives
- Insulin - pharmacokinetics
- Insulin Detemir -
- Insulin, Isophane - administration & dosage
- Insulin, Isophane - pharmacokinetics
- Insulin, Long-Acting -
- Male -